Transcranial Magnetic Stimulation for Parkinson's Disease

Overseen By Tomoha Ogawa, BA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: McGill University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

24 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to understand how a specific brain area, the Posterior Parietal Cortex (PPC), plays a role in movement transfer from walking on a split-belt treadmill (SBT) to walking on the ground in people with Parkinson's disease (PwPD).

Here, investigators will apply repeated transcranial magnetic stimulation (rTMS) to upregulate the PPC. Then, the differences in the gait parameters between pre- and post-interventions will be compared between the TMS-active and the TMS-sham.

Who Is on the Research Team?

Caroline Paquette, PhD

Principal Investigator

McGill University

Are You a Good Fit for This Trial?

This trial is for individuals with Parkinson's Disease who are interested in participating in a study to understand brain function related to movement. Specific eligibility criteria details were not provided, so it's best to contact the study team for more information on who can join.

Inclusion Criteria

I have been diagnosed with Parkinson's disease.

No previous experience with split-belt treadmill

No mild cognitive impairment (Montreal Cognitive Assessment ≥ 25)

Exclusion Criteria

Implanted deep brain stimulator

I have severe movement issues affecting my walking and balance.

I cannot walk safely on a moving treadmill.

What Are the Treatments Tested in This Trial?

Interventions

• Transcranial Magnetic Stimulation Active
• Transcranial Magnetic Stimulation Sham

Trial Overview

The trial is testing how applying repeated transcranial magnetic stimulation (rTMS) affects walking ability after using a split-belt treadmill. Participants will be divided into two groups: one receiving active rTMS and the other receiving sham (placebo) treatment.

How Is the Trial Designed?

Group I: Sham rTMS First followed by Active rTMS Second Experimental Treatment 2 Interventions

Session 1: sham rTMS (iTBS) over the right PPC Session 2: active rTMS (iTBS) over the right PPC

Group II: Active rTMS First followed by Sham rTMS Second Experimental Treatment 2 Interventions

Session 1: active rTMS (iTBS) over the right PPC Session 2: sham rTMS (iTBS) over the right PPC

Who Is Running the Clinical Trial?

McGill University

Lead Sponsor

Trials

421

Recruited

1,017,000+